Brief Report THROMBOSIS AND HEMOSTASIS FVIIa as used pharmacologically is not TF dependent in hemophilia B mice


Human coagulation factor VIIa is approved to treat bleeding in hemophilia patients with inhibitors. Two theories attempt to explain whyhighdoses of FVIIa are required for hemostasis. The tissue factor (TF)-dependent mechanism suggests that FVIIa’s hemostatic effect requires its binding to TF, which is expressed on cell surfaces at the site of injury. In… (More)


2 Figures and Tables